Business Wire

ELLIOTT-ADVISORS-UK

Share
Elliott Releases Presentation on Sampo

Elliott Advisors (UK) Limited (“Elliott” or “we”), which advises funds that as at the date of this release collectively hold investments equivalent to more than 3% of the share capital of Sampo Oyj (“Sampo” or the “Company”), today published a new presentation outlining a clear pathway to transform Sampo into a pure-play insurer and create in excess of EUR 8 billion of value.

Whilst Sampo’s announcement of 10 November 2020 was a positive first step towards making the structural simplifications necessary to re-establish the Company’s reputation among investors, Sampo’s shares have continued to underperform. Today, Sampo’s high quality core insurance business trades at an unmerited ~5x P/E discount to its peers; this sits in stark contrast to the ~4x P/E premium the business used to trade at several years ago.

Elliott believes that Sampo’s upcoming Capital Markets Day (“CMD”) on 24 February 2021 is the opportune moment for the Company to reverse this historical underperformance and value destruction, highlight its strengths and restore investor confidence. As such, Elliott encourages Sampo to:

  1. Simplify the Portfolio : Sampo should announce that it plans to become a pure-play insurer by Q4 2021. The Company’s Nordea stake is widely acknowledged to have become a significant distraction and a sustained drag on valuation for Sampo. In a survey of investors commissioned by Elliott, the vast majority of respondents indicated they would like to see a full exit from the Nordea stake within the next twelve months. Sampo is positioned to satisfy investor demands by distributing half of Sampo’s Nordea shares directly to shareholders – an act that over two-thirds of investors surveyed are supportive of – in Q2 2021 and selling the remainder to maintain a healthy balance sheet.
  2. Clarify the Strategy : Importantly, Sampo should assert that without the overhang of the Nordea stake, the Company will commit to being a dividend-focused P&C insurer, with no material M&A ambitions outside the Nordics until the Hastings deal proves successful. We believe that there is widespread confusion amongst investors about the Sampo equity story, including scepticism on the rationale for the Hastings transaction and Sampo’s future M&A appetite. What is clear is that investors are seeking greater focus on stable dividends, viewed as the lifeblood of a highly rated insurance company, and a commitment by Sampo to become a focused P&C insurer. The stability and growth prospects of IF P&C ideally position Sampo to become the stable dividend payer that investors seek; however, concerns about Sampo’s capital allocation strategy must be resolved before the market can give Sampo the credit it deserves.
  3. Enhance the Communications : IF P&C is Sampo’s crown jewel. Sampo should clearly and confidently articulate IF P&C’s strong fundamentals and provide the market with relevant, timely and specific targets and KPIs. Shining a spotlight on IF P&C will enable Sampo to recover its premium valuation.

Elliott believes that these measures and the transformation of Sampo into a pure-play insurer would collectively restore investor confidence and unlock in excess of EUR 8 billion in value for Sampo’s shareholders.

Elliott today launched a new website www.SimplifyingSampo.com , where Elliott’s presentation is available to view and download in full. Interested parties are encouraged to visit the website to receive additional information and to sign up for future updates.

About Elliott

Elliott Investment Management L.P. manages approximately $41 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Investment Management L.P.

Disclaimer

Elliott intends to reviews its investments in the company on a continuing basis and depending upon various factors, including without limitation, the company’s financial position and strategic direction, the outcome of any discussions with the company, overall market conditions, other investment opportunities available to Elliott Management, and the availability of company securities at prices that would make the purchase or sale of company securities desirable, Elliott may from time to time (in the open market or in private transactions, including since the inception of Elliott position) buy, sell, cover, hedge or otherwise change the form or substance of any of its investments (including company securities) to any degree in any manner permitted by law and expressly disclaims any obligation to notify others of any such changes. Elliott also reserves the right to take any actions with respect to its investments in the company as it may deem appropriate.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis26.10.2025 01:55:00 CEST | Press release

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of patients treated with Opzelura achieved a ≥75% improvement in the Eczema Area and Severity Index (EASI75) and 61.3% achieved Investigator’s Global Assessment Treatment Success (IGA-TS), co-primary endpoints of the study Based on these results, Incyte expects to file a Type-II variation application for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU) by end of year Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moder

MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem25.10.2025 10:24:00 CEST | Press release

MultiBank Group, the world’s largest financial derivatives institution, has entered into an exclusive worldwide multi-billion-dollar joint venture with global sports icon and undefeated UFC champion Khabib Nurmagomedov (29-0) to create a first-of-its-kind regulated ecosystem connecting global finance, sports and technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251025540563/en/ MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem The partnership will culminate in the creation of a multi-billion-dollar joint venture, MultiBank Khabib LLC, uniting two global powerhouses: MultiBank Group, a leader in regulated financial excellence, and Khabib Nurmagomedov, undefeated in the octagon and whose influence extends far beyond sport.The company will operate from MultiBank Group’s headquarters in Dubai, building

Altimetrik Completes Acquisition of SLK Software, Uniting Strengths to Unlock Value through AI-First and Digital Enablement24.10.2025 18:57:00 CEST | Press release

Altimetrik today announced the successful completion of its acquisition of SLK Software, marking a major milestone in the company’s journey to build a digital engineering powerhouse. As part of this transition, SLK Software will now operate under its new identity as “SLK, an Altimetrik company”. The integration brings together Altimetrik’s AI-first, data-led innovation capabilities with SLK’s strength in Intelligent Enterprise, Digital Operations, Intelligent Infrastructure and Automation and Quality Engineering - spanning the entire digital enablement value chain from strategy and design to engineering and managed services. Anchored in a Practitioner-Led approach, the unified organization merges deep domain expertise with modern platforms and digital operating models to deliver bite-size, outcome-focused execution that accelerates time-to-value. “I am thrilled to officially welcome the SLK team to Altimetrik, bringing together two organizations driven by purpose, innovation, and an un

Andersen Consulting samarbejder med Acronotics om at udbygge AI-styrede digitale transformationskapaciteter24.10.2025 17:55:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Acronotics, et hurtigt voksende digitalt konsulentfirma med hovedsæde i Storbritannien og afdelinger i USA og Indien. Som specialist i AI-drevet forretningstransformation samarbejder Acronotics med Fortune 500-virksomheder om at fremskynde den digitale transformation ved hjælp af kunstig intelligens. Virksomheden har dyb ekspertise inden for produktion, bankvirksomhed og finansielle tjenester, detailhandel, hurtigt omsættelige forbrugsgoder og højteknologiske industrier med stærkt fokus på AI/ML, generativ AI og RPA-teknologi. Acronotics leverer end-to-end-tjenester, herunder design, udvikling og implementering af Agentic AI og RPA-baserede procesautomatiseringsløsninger. Ved hjælp af sin egenudviklede automatiserede digitale medarbejderstyringsplatform, Radium.ai, hjælper virksomheden sine kunder med at administrere og overvåge deres digitale arbejdsstyrke effek

LambdaTest Unveils AI-Powered Web Scanner for Scalable Visual and Accessibility Testing24.10.2025 17:00:00 CEST | Press release

New browser-based solution empowers teams to detect visual bugs and ensure accessibility compliance at scale LambdaTest, a GenAI-native quality engineering platform, today announced the launch of LambdaTest Web Scanner, an advanced browser-based tool combining Visual UI Regression Testing and WCAG-compliant Accessibility Testing. It enables teams to identify and resolve visual and accessibility issues across web applications with unparalleled speed and precision. LambdaTest Web Scanner combines key features to streamline visual and accessibility testing. It offers Visual UI Regression Testing with SmartUI technology, enabling automated scans that detect layout changes and design mismatches across browsers and screen resolutions. It also supports WCAG-compliant Accessibility Testing, identifying violations and providing recommendations for inclusivity. The tool enables cross-browser and responsive testing across multiple browsers and 200+ mobile viewports, while smart scheduling allows

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye